Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Gene Rank description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 1352 to 1401 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1352\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CCAAT-BOX-BINDING TRANSCRIPTION FACTOR (CCAAT-BINDING FACTOR) (CBF). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.462442\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.88643\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245141352\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CEBPZ\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1353\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RING FINGER PROTEIN 20. \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.188445\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.768755\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.245130113\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
RNF20\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1354\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RING FINGER PROTEIN 40; 95 KDA RETINOBLASTOMA PROTEIN BINDING PROTEIN; LIKELY ORTHOLOG OF RAT STARING. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
RNF40\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1355\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0726736\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.296523\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.245085879\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
TTLL12\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1356\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ZINC-FINGER PROTEIN ZPR1 (ZINC FINGER PROTEIN 259). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
ZNF259\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1357\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ELONGATION FACTOR 1-ALPHA 2 (EF-1-ALPHA-2) (ELONGATION FACTOR 1 A-2) (EEF1A-2) (STATIN S1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.145347\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.593047\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245085128\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EEF1A2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1358\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ELONGATION FACTOR 1-ALPHA 1 (EF-1-ALPHA-1) (ELONGATION FACTOR 1 A-1) (EEF1A-1) (ELONGATION FACTOR TU) (EF-TU). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.14659\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.598119\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245085008\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EEF1AL3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1359\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MYB-RELATED PROTEIN A (A-MYB). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.106233\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.433454\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24508483\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MYBL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1360\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEASOME SUBUNIT BETA TYPE 5 PRECURSOR (EC 3.4.25.1) (PROTEASOME EPSILON CHAIN) (MACROPAIN EPSILON CHAIN) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX EPSILON CHAIN) (PROTEASOME SUBUNIT X) (PROTEASOME CHAIN 6) (PROTEASOME SUBUNIT MB1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.779006\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.17883\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245060604\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMB5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1361\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSLATION INITIATION FACTOR IF-2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.588043\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.39991\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245027105\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EIF5B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1362\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.596229\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.43411\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244947435\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1363\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ATP-DEPENDENT RNA HELICASE DDX24 (DEAD-BOX PROTEIN 24). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.230116\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.939561\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244918638\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DDX24\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1364\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HISTONE H2B.C (H2B/C). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0938754\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.38338\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244862538\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HIST1H2BL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1365\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HISTONE H2B.D (H2B/D). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0957148\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.390892\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24486252\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1366\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"TESTIS-SPECIFIC HISTONE H2B; H2B HISTONE FAMILY, MEMBER U, (TESTIS-SPECIFIC). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0836563\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.341646\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244862519\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HIST1H2BA\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1367\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HISTONE H2B.E (H2B/E). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0942586\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.384945\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244862513\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
1368\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HISTONE H3.1 (H3/A) (H3/C) (H3/D) (H3/F) (H3/H) (H3/I) (H3/J) (H3/K) (H3/L). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.157068\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.641454\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244862453\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1369\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HISTONE H2B.Q (H2B/Q) (H2B-GL105). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0960725\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.392353\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244862407\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HIST2H2BA\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1370\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HISTONE H2B.S (H2B/S). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0946163\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.386406\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244862399\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
1371\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HISTONE H2B. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0943097\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.385154\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244862315\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1372\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HISTONE H3.4 (H3T) (H3/T) (H3/G). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.147768\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.603475\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244861842\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HIST3H3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1373\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.403732\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.64923\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244800301\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ARID4B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1374\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MKI67 (FHA DOMAIN) INTERACTING NUCLEOLAR PHOSPHOPROTEIN; NUCLEOLAR PHOSPHOPROTEIN NOPP34; NUCLEOLAR PROTEIN INTERACTING WITH THE FHA DOMAIN OF PKI-67. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.467786\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.91164\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244704024\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MKI67IP\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1375\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEASOME SUBUNIT ALPHA TYPE 2 (EC 3.4.25.1) (PROTEASOME COMPONENT C3) (MACROPAIN SUBUNIT C3) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT C3). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.02216\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4.1775\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244682226\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMA2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1376\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.149037\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.609191\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244647409\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C14orf129\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1377\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HOMEOBOX PROTEIN PRH (HEMATOPOIETICALLY EXPRESSED HOMEOBOX) (HOMEOBOX PROTEIN HEX). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.18361\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.750509\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244647299\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HHEX\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1378\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GLYCOGEN SYNTHASE KINASE-3 BETA (EC 2.7.1.37) (GSK-3 BETA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.034279\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.140116\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244647292\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GSK3B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1379\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SUPPRESSOR OF VAR1, 3-LIKE 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0439474\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.179636\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244646953\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SUPV3L1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1380\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BAG-FAMILY MOLECULAR CHAPERONE REGULATOR-1 (BCL-2 BINDING ATHANOGENE- 1) (BAG-1) (GLUCOCORTICOID RECEPTOR-ASSOCIATED PROTEIN RAP46). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.200609\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.819994\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244646912\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BAG1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1381\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GLYCOGEN SYNTHASE KINASE-3 ALPHA (EC 2.7.1.37) (GSK-3 ALPHA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0268629\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.109803\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244646321\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GSK3A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1382\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.191835\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.784198\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24462572\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DDX55\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1383\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ATAXIN-1 UBIQUITIN-LIKE INTERACTING PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.427194\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.74675\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244565049\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UBQLN4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1384\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UBIQUILIN 1 ISOFORM 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.508151\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.0779\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244550267\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UBQLN1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1385\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AUTOANTIGEN NGP-1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.28719\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.17469\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244481523\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GNL2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1386\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BA271B5.1 (SIMILAR TO RIBOSOMAL PROTEIN S7). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.037776\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.154523\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244468461\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1387\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
APOLIPOPROTEIN B-100 PRECURSOR (APO B-100) [CONTAINS: APOLIPOPROTEIN B-48 (APO B-48)]. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0307397\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.125741\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244468391\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
APOB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1388\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
40S RIBOSOMAL PROTEIN S7 (S8). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.038293\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.156638\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244468137\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RPS7\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1389\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
26S PROTEASOME-ASSOCIATED PAD1 HOMOLOG. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.1639\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4.76096\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244467502\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMD14\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1390\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.410655\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.68007\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244427316\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1391\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRIFUNCTIONAL PURINE BIOSYNTHETIC PROTEIN ADENOSINE-3 [INCLUDES: PHOSPHORIBOSYLAMINE--GLYCINE LIGASE (EC 6.3.4.13) (GARS) (GLYCINAMIDE RIBONUCLEOTIDE SYNTHETASE) (PHOSPHORIBOSYLGLYCINAMIDE SYNTHETASE); PHOSPHORIBOSYLFORMYLGLYCINAMIDINE CYCLO-LIGASE (EC 6.\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.131799\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.53927\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244402618\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GART\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1392\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.038432\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.157255\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244392865\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
WDR82\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1393\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.336304\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.37608\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244392768\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ABCF3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1394\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UBIQUITIN-CONJUGATING ENZYME E2 A (EC 6.3.2.19) (UBIQUITIN-PROTEIN LIGASE A) (UBIQUITIN CARRIER PROTEIN A) (HR6A) (HHR6A). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.240046\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.982761\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244256742\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UBE2A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1395\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MYOSIN VIIA. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.066057\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.270441\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244256603\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MYO7A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1396\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UBIQUITIN-CONJUGATING ENZYME E2 B (EC 6.3.2.19) (UBIQUITIN-PROTEIN LIGASE B) (UBIQUITIN CARRIER PROTEIN B) (HR6B) (HHR6B) (E2-17 KDA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.222353\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.910326\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244256453\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UBE2B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1397\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EUKARYOTIC TRANSLATION INITIATION FACTOR 2 SUBUNIT 3 (EUKARYOTIC TRANSLATION INITIATION FACTOR 2 GAMMA SUBUNIT) (EIF-2-GAMMA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.361623\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.48057\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244245797\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EIF2S3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1398\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MEGF6 (FRAGMENT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.11514\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.471496\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244201435\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MEGF6\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1399\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0746708\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.305803\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244179423\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
LSG1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1400\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEASOME SUBUNIT ALPHA TYPE 4 (EC 3.4.25.1) (PROTEASOME COMPONENT C9) (MACROPAIN SUBUNIT C9) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT C9) (PROTEASOME SUBUNIT L). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.529846\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.17049\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244113541\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMA4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1401\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DOUBLECORTIN (LISSENCEPHALIN-X) (LIS-X) (DOUBLIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.303311\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.24261\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.244091871\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DCX\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/